Tolvaptan in euvolemic hyponatremia

PreclinicalSmall molecule

Tolvaptan in euvolemic hyponatremia is one of 5 small molecule programs targeting Hyponatremia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyponatremiaActive, not recruiting

HyponatremiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Hyponatremia

#DrugCompanyPhaseTrials

Samsca

Otsuka

Approved

16 2

Jardiance

Boehringer Ingelheim

Approved

2 3

Proamatine

Takeda

Preclinical

1 4

PEG-ELS

Ferring

Preclinical

1 5

Tolvaptan in euvolemic hyponatremia

NNYU Langone Health

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hyponatremia1 trial

Fractional Urate Excretion in Nonedematous Hyponatremia

Withdrawn·NNYU Langone Health·N/A·NCT01425125

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tolvaptan in euvolemic hyponatremia. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tolvaptan in euvolemic hyponatremia compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tolvaptan in euvolemic hyponatremia. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NYU Langone Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNYU Langone Health

Tolvaptan in euvolemic hyponatremia

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hyponatremia1 trial

References

Drug Info

Quick Facts

Related News